
<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>Eosinophilic Esophagitis (EoE): A Consolidated Guideline View</title>
<style>

<style>
/* ===== GENERAL LAYOUT ===== */
body {
    font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
    background: linear-gradient(135deg, #eef2ff, #fafafa);
    color: #2c2c2c;
    padding: 30px;
    margin: 0;
}

/* Centered mindmap container */
.mindmap {
    max-width: 800px;
    margin: auto;
    font-size: 20px;
    line-height: 1.7;
}

/* ===== LISTS ===== */
.mindmap ul {
    margin: 0.6em 0 1em 1.5em;
    padding-left: 1.4em;
    list-style: disc;
    color: #555;
    font-size: 0.95em;
    font-weight: 400;
    line-height: 1.6;
}

.mindmap li::marker {
    color: #8b5cf6; /* accent bullet color */
}

.mindmap li {
    margin-bottom: 6px;
    padding-left: 4px;
}

/* ===== COLLAPSIBLE SECTIONS ===== */
.mindmap details {
    /* FIX: Increased border width and used a darker color */
    border-left: 5px solid #7c3aed; 
    background: #ffffff;
    margin: 8px 0;
    /* FIX: Corrected typo "20x" to "20px" */
    padding: 9px 25px; 
    border-radius: 20px;
    box-shadow: 0 4px 12px rgba(139, 92, 246, 0.1);
    transition: all 0.3s ease;
    position: relative;
}

/* Subsection (nested details) */
.mindmap details > div > details {
    margin-left: -8px;
    /* FIX: Used a darker, more saturated color for the nested border */
    border-color: #9333ea; 
    background: #faf7ff;
}

/* Subtle hover feedback */
.mindmap details:hover {
    box-shadow: 0 6px 18px rgba(139, 92, 246, 0.18);
    background: linear-gradient(135deg, #ffffff, #f5f0ff);
}

/* ===== SUMMARY HEADERS ===== */
.mindmap summary {
    cursor: pointer;
    font-size: 1.1em;
    font-weight: 600;
    list-style: none;
    position: relative;
    /* FIX: Increased padding slightly to prevent text from touching the arrow icon */
    padding-left: 24px; 
    color: #4c1d95;
    outline: none;
}

/* Custom arrow icon */
.mindmap summary::before {
    content: "▶";
    position: absolute;
    left: 0;
    top: 2px;
    transition: transform 0.3s ease;
    font-size: 1em;
    color: #7c3aed;
}

/* Rotated arrow when open */
.mindmap details[open] > summary::before {
    transform: rotate(90deg);
}

/* Section title emphasis */
.mindmap summary strong {
    display: block;
    font-size: 1.25em;
    color: #4c1d95;
}

.mindmap summary em {
    font-style: normal;
    color: #6b21a8;
    font-size: 0.95em;
}

/* Open section highlighting */
.mindmap details[open] > summary {
    background: #f3e8ff;
    border-radius: 8px;
    padding: 6px 10px;
}

/* Smooth fade for expanded content */
.mindmap details[open] > div {
    animation: fadeIn 0.3s ease-in;
}

/* ===== DESCRIPTION BOXES ===== */
.mindmap .desc-box {
    background: #fdfcff;
    border: 2px solid #e5d9fb;
    border-left: 4px solid #c084fc;
    padding: 6px 10px;
    margin: 12px 0 18px 0;
    border-radius: 12px;
    box-shadow: 0 1px 3px rgba(160, 104, 255, 0.05);
    transition: background 0.3s ease;
}
.mindmap .desc-box:hover {
    background: #f8f4ff;
}

/* ===== ANIMATIONS ===== */
@keyframes fadeIn {
    from { opacity: 0; transform: translateY(-3px); }
    to { opacity: 1; transform: translateY(0); }
}

/* ===== BUTTONS ===== */
button {
    background-color: #7c3aed;
    color: white;
    border: none;
    padding: 10px 16px;
    margin: 0 6px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
button:hover {
    background-color: #6b21a8;
    transform: scale(1.05);
}

/* ===== FLOATING CONTROL PANEL ===== */
#level-controls {
    position: fixed;
    bottom: 30px;
    left: 85%;
    transform: translateX(-50%);
    background: rgba(255, 255, 255, 0.05);
    padding: 10px 16px;
    border-radius: 12px;
    box-shadow: 0 4px 12px rgba(0, 0, 0, 0.15);
    z-index: 9999;
    backdrop-filter: blur(6px);
    cursor: move;
    display: flex;
    align-items: center;
    gap: 6px;
}

/* Buttons inside the panel */
#level-controls button {
    background-color: rgba(124, 58, 237, 0.85);
    color: white;
    border: none;
    padding: 8px 14px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
#level-controls button:hover {
    background-color: rgba(107, 33, 168, 0.95);
    transform: scale(1.05);
}

/* Search input inside panel */
#level-controls input {
    border: 1px solid #d5c4ff;
    border-radius: 8px;
    padding: 7px 10px;
    font-size: 0.95em;
    outline: none;
    width: 150px;
    transition: border-color 0.2s ease;
}
#level-controls input:focus {
    border-color: #8b5cf6;
}

/* Search count text */
#searchCount {
    margin-left: 8px;
    font-style: italic;
    color: #4c1d95;
    font-size: 0.9em;
}

/* ===== SEARCH HIGHLIGHT ===== */
mark.search-highlight {
    background-color: #fff59d;
    color: #000;
    border-radius: 3px;
    padding: 1px 3px;
}



/* ===== CLICK-TO-REVEAL: Spoiler Blur Style ===== */
.mindmap q {
    cursor: pointer;
    color: transparent;
    /* Apply a text-shadow with the same color as the text to create the blur effect */
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease;
}

.mindmap q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* Style for the revealed text */
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}




/*for full control button*/
/* ===== CLICK-TO-REVEAL: Spoiler Blur Style (with Read Mode) ===== */

/* This rule applies the blur ONLY when the mindmap is NOT in read-mode. */
.mindmap:not(.read-mode) q {
    cursor: pointer;
    color: transparent;
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease, color 0.3s ease;
}

.mindmap:not(.read-mode) q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* This combined rule handles BOTH cases for revealing text:
   1. The entire mindmap is in read-mode.
   2. An individual <q> has been clicked (in quiz mode).
*/
.mindmap.read-mode q,
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}


</style>

</style>
</head>
<body>

<!-- Updated Controls -->
<div id="level-controls" onmousedown="dragElement(this)">
    <button onclick="zoomIn()">+</button>
    <button onclick="zoomOut()">-</button>
    <button onclick="resetView()">=</button>
    <!-- NEW: READ MODE TOGGLE BUTTON -->
    <button onclick="toggleReadMode()">Q/R</button>
</div>

<div class="mindmap">

    <div class="mindmap">
        
        <details>
            <summary><strong>Eosinophilic Esophagitis (EoE): A Consolidated Guideline View</strong></summary>
            <div>
                <ul><li>- This mind map synthesizes and compares two major clinical guidelines on Eosinophilic Esophagitis (EoE).</li><li>- <b>Source 1 (ACG)</b>: ACG Clinical Guideline: Diagnosis and Management of Eosinophilic Esophagitis (Dellon et al., Am J Gastroenterol 2025).</li><li>- <b>Source 2 (BSG)</b>: British Society of Gastroenterology (BSG) and British Society of Paediatric Gastroenterology, Hepatology and Nutrition (BSPGHAN) joint consensus guidelines (Dhar et al., Gut 2022).</li></ul>
                
        <details>
            <summary><strong>Knowledge Test</strong></summary>
            <div>
                <ul><li>- What is the BSG's specific recommendation for PPI withdrawal before a diagnostic endoscopy for EoE?</li><li>- What is the histologic remission target for treated EoE, according to the BSG?</li><li>- What is the ACG-cited efficacy of a 6-food elimination diet (6FED) in achieving histologic remission?</li><li>- According to the ACG, what is the FDA-approved weekly dose of dupilumab for adults with EoE?</li><li>- Both guidelines agree that esophageal dilation is safe, but what is the perforation risk cited by the ACG?</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Definition & Diagnosis</strong></summary>
            <div>
                <ul><li>- EoE is a chronic, immune/antigen-mediated esophageal disease.</li></ul>
                
        <details>
            <summary><strong>Core Diagnostic Criteria (Consensus)</strong></summary>
            <div>
                <ul><li>- <b>1. Symptoms</b> of esophageal dysfunction (e.g., dysphagia, food impaction).</li><li>- <b>2. Histology</b>: Esophageal biopsy showing a peak eosinophil count of <q><b>≥15 eosinophils/high-power field (eos/hpf)</b></q>.</li><li>- <b>3. Exclusion</b>: Evaluation for other causes of esophageal eosinophilia (e.g., GERD, eosinophilic gastroenteritis, Crohn's disease).</li></ul>
                
        <details>
            <summary><strong>Histologic Threshold Nuances (BSG)</strong></summary>
            <div>
                <ul><li>- BSG proposes updating the definition to account for digital microscopy.</li><li>- Recommends expressing the count as <q>≥15 eosinophils/0.3 mm²</q> or <q>>60 eosinophils/mm²</q>.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Role of PPIs in Diagnosis (Paradigm Shift)</strong></summary>
            <div>
                <ul><li>- <b>Consensus</b>: A trial of Proton Pump Inhibitors (PPIs) is <u>no longer required</u> to diagnose EoE.</li><li>- The term 'PPI-responsive esophageal eosinophilia' (PPI-REE) is obsolete.</li><li>- PPIs are now considered a <b>treatment</b> for EoE, not a diagnostic tool.</li></ul>
                
        <details>
            <summary><strong>Pre-Diagnostic PPI Use: A Point of Difference</strong></summary>
            <div>
                <ul><li>- <b>BSG (Strong Recommendation)</b>: PPIs should be withdrawn for at least <q><b>3 weeks</b></q> prior to a diagnostic endoscopy to avoid false negatives.</li><li>- <b>ACG (Advisory)</b>: Advises performing endoscopy on <u>no treatment</u> (including no PPIs) to maximize diagnostic sensitivity, but does not specify a mandatory withdrawal period.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Clinical Presentation</strong></summary>
            <div>
                <ul><li>- Symptoms vary significantly with age.</li></ul>
                
        <details>
            <summary><strong>Adults & Adolescents</strong></summary>
            <div>
                <ul><li>- Most common: <b>Dysphagia</b> and <b>food impaction</b>.</li><li>- Other symptoms: Heartburn, chest pain.</li><li>- ACG highlights assessing for 'IMPACT' behaviors (Imbibe fluids, Modify foods, Prolong meals, Avoid hard textures, Chew excessively, Turn away tablets) which can mask dysphagia severity.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Children</strong></summary>
            <div>
                <ul><li>- <b>Infants/Young Children</b>: Feeding intolerance, food refusal, failure to thrive, poor growth.</li><li>- <b>School-aged Children</b>: Abdominal pain, vomiting, regurgitation, heartburn.</li><li>- BSG notes symptoms are often non-specific and vary with age.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Risk Factors & Associations</strong></summary>
            <div>
                <ul><li>- <b>Atopy (Consensus)</b>: Strong association with other atopic diseases (asthma, allergic rhinitis, eczema). ACG notes <q>60%-80%</q> of EoE patients have concomitant allergic conditions.</li><li>- <b>Genetics (Consensus)</b>: Family history increases risk. BSG notes a first-degree relative increases risk significantly.</li><li>- <b>Demographics (BSG)</b>: More common in <u>men</u> (3:1 ratio) and people of <u>white ethnic origin</u>.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Endoscopic & Histologic Evaluation</strong></summary>
            <div>
                <ul><li>- Endoscopy with biopsy is essential for diagnosis, monitoring, and assessing treatment response.</li></ul>
                
        <details>
            <summary><strong>Endoscopic Findings</strong></summary>
            <div>
                <ul><li>- Typical features: Edema, fixed rings, white exudates, linear furrows, strictures, crepe-paper mucosa.</li><li>- <b>Consensus Recommendation</b>: Use a systematic scoring system at every endoscopy.</li></ul>
                
        <details>
            <summary><strong>EoE Endoscopic Reference Score (EREFS)</strong></summary>
            <div>
                <ul><li>- Specifically recommended by <b>ACG</b> for standardizing reports.</li><li>- Grades 5 features: <b>E</b>dema, <b>R</b>ings, <b>E</b>xudates, <b>F</b>urrows, <b>S</b>trictures.</li><li>- Score range: <q>0-9</q>. A post-treatment score of <q>≤2</q> is a proposed threshold for response.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Endoscopic Underestimation (BSG)</strong></summary>
            <div>
                <ul><li>- BSG emphasizes that endoscopists can <u>underestimate</u> the frequency of strictures and narrow-lumen esophagus.</li><li>- ACG concurs, citing studies where endoscopy had poor sensitivity (<q>15%</q>) for detecting narrowing compared to esophagram.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Biopsy Protocol (Consensus)</strong></summary>
            <div>
                <ul><li>- <b>Recommendation</b>: Obtain at least <q><b>6 esophageal biopsies</b></q>.</li><li>- Biopsies should be from at least <b>2 different levels</b> (e.g., proximal/mid and distal esophagus).</li><li>- ACG advises targeting visible abnormalities (furrows, exudates) to increase diagnostic yield.</li></ul>
                
        <details>
            <summary><strong>Biopsy During Food Impaction</strong></summary>
            <div>
                <ul><li>- <b>Consensus</b>: Biopsies <u>should be taken</u> at the time of endoscopy for food bolus obstruction after the bolus is cleared.</li><li>- This is a critical opportunity for diagnosis that is often missed.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Histologic Assessment</strong></summary>
            <div>
                <ul><li>- <b>Primary Feature</b>: Peak eosinophil count.</li><li>- <b>Consensus</b>: Eosinophil counts must be quantified on every biopsy report, not just stated as '>15'.</li></ul>
                
        <details>
            <summary><strong>Other Histologic Features</strong></summary>
            <div>
                <ul><li>- Both guidelines note other important features beyond eosinophils.</li><li>- <b>BSG</b>: Basal cell hyperplasia, edema (spongiosis), eosinophil microabscesses, subepithelial sclerosis.</li><li>- <b>ACG</b>: Mentions the EoE Histologic Scoring System (EoEHSS) which assesses 8 features, including lamina propria fibrosis.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Defining Histologic Remission (BSG)</strong></summary>
            <div>
                <ul><li>- BSG provides specific definitions for clinical use:</li><li>- <b>Remission</b>: Maximum eosinophil count <q><15 eos/0.3 mm²</q>.</li><li>- <b>Deep/Complete Remission</b>: Maximum eosinophil count <q><5 eos/0.3 mm²</q>.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Management: The 3 D's (Drugs, Diet, Dilation)</strong></summary>
            <div>
                <ul><li>- Treatment goals: Improve symptoms, resolve inflammation (histologic/endoscopic remission), and prevent complications (fibrostenosis).</li><li>- <b>Consensus</b>: Treatment choice should be based on shared decision-making between the clinician and patient.</li></ul>
                
        <details>
            <summary><strong>Proton Pump Inhibitors (PPIs)</strong></summary>
            <div>
                <ul><li>- <b>Consensus</b>: PPIs are an effective first-line treatment for EoE.</li><li>- Mechanism is beyond acid suppression; includes anti-inflammatory effects like decreasing <b>eotaxin-3</b> expression and improving barrier function (ACG).</li></ul>
                
        <details>
            <summary><strong>Efficacy</strong></summary>
            <div>
                <ul><li>- ACG meta-analysis: Pooled histologic remission (<15 eos/hpf) of <q><b>50.5%</b></q> and clinical response of <q><b>60.8%</b></q>.</li><li>- BSG meta-analysis: Similar pooled rate of <q><b>51%</b></q> for histologic remission.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Dosing Recommendations</strong></summary>
            <div>
                <ul><li>- <b>ACG</b>: Recommends 'high-dose' PPI, which is double the approved reflux dose (e.g., omeprazole <q>20mg twice daily</q> or <q>40mg once daily</q>).</li><li>- <b>BSG</b>: Recommends twice-daily dosing for at least <q>8-12 weeks</q> before assessing response.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Topical Corticosteroids (STCs)</strong></summary>
            <div>
                <ul><li>- <b>Consensus</b>: A highly effective first-line treatment for inducing clinical and histologic remission.</li></ul>
                
        <details>
            <summary><strong>Efficacy</strong></summary>
            <div>
                <ul><li>- <b>ACG</b>: Meta-analyses show histologic response rates in the <q>60%-70%</q> range. Phase 3 trials of newer formulations show rates from <q>62% to 95%</q>.</li><li>- <b>BSG</b>: Rates STCs as more effective than PPIs but less effective than topical budesonide preparations in a meta-analysis.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Formulations & Dosing</strong></summary>
            <div>
                <ul><li>- Common agents: <b>Budesonide</b> and <b>Fluticasone</b>.</li><li>- <b>ACG</b>: Mentions FDA-approved Budesonide Oral Suspension (BOS) and EMA-approved Budesonide Orodispersible Tablet (BOT), as well as off-label slurries and swallowed inhalers.</li><li>- <b>BSG</b>: Supports use of <u>orodispersible budesonide (BOT)</u> for induction in adults and oral viscous budesonide (OVB) for children.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Adverse Effects</strong></summary>
            <div>
                <ul><li>- <b>Consensus</b>: Most common side effect is oropharyngeal/esophageal <b>candidiasis</b>.</li><li>- <b>ACG</b>: Cites rates from <q>3.8% (BOS)</q> to <q>23.7% (BOT)</q> in trials.</li><li>- <b>Adrenal Insufficiency</b>: Uncommon. ACG notes it's <q>≤5%</q> in trials. BSG recommends monitoring for it in children/adolescents on long-term therapy.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Dietary Elimination Therapy</strong></summary>
            <div>
                <ul><li>- <b>Consensus</b>: An effective treatment option, but requires significant patient commitment and dietitian support.</li></ul>
                
        <details>
            <summary><strong>Empiric vs. Allergy Test-Directed Diets</strong></summary>
            <div>
                <ul><li>- <b>Strong Consensus</b>: <u>Do not use</u> currently available allergy testing (skin prick, patch, serum IgE/IgG) to guide food elimination for EoE.</li><li>- Allergy test-directed diets have the lowest response rates (<q>~45%</q>).</li><li>- <b>Empiric elimination</b> is the recommended approach.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Types of Empiric Diets & Efficacy</strong></summary>
            <div>
                <ul><li>- <b>Elemental Diet</b>: Amino acid-based formula. Highest efficacy (<q>>90%</q>) but poor palatability and adherence.</li><li>- <b>6-Food Elimination Diet (6FED)</b>: Eliminates milk, wheat, soy, egg, nuts, fish/shellfish. Efficacy <q>~70%</q>.</li><li>- <b>4-Food (4FED) & 2-Food (2FED)</b>: Less restrictive. Efficacy <q>~40-50%</q>.</li><li>- <b>1-Food (1FED)</b>: Milk elimination alone. Efficacy <q>~35-45%</q>.</li></ul>
                
        <details>
            <summary><strong>Approach to Diet Selection</strong></summary>
            <div>
                <ul><li>- <b>ACG</b>: Suggests starting with a less restrictive diet (1FED or 2FED) is a reasonable initial choice.</li><li>- <b>BSG</b>: Recommends a 'step-up' approach, starting with a 2FED and escalating if no response.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Food Reintroduction</strong></summary>
            <div>
                <ul><li>- <b>Consensus</b>: After a response to an elimination diet, foods must be reintroduced systematically to identify triggers.</li><li>- This requires a repeat endoscopy with biopsies after each food/food group is added back for <q>6-8 weeks</q>.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Biologics</strong></summary>
            <div>
                <ul><li>- A newer class of therapy for moderate-to-severe or refractory EoE.</li></ul>
                
        <details>
            <summary><strong>Dupilumab (Anti-IL-4/IL-13)</strong></summary>
            <div>
                <ul><li>- <b>ACG (Conditional Recommendation)</b>: Suggests dupilumab for patients ≥1 year old who are non-responsive to PPI therapy.</li><li>- <b>Efficacy (Adults/Adolescents)</b>: Achieved histologic remission (≤6 eos/hpf) in <q><b>60%</b></q> of patients vs. 5% in placebo.</li><li>- <b>Dosing</b>: <q>300mg subcutaneously <b>weekly</b></q> for patients ≥40kg. Dosing is every other week for younger/lighter patients.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Other Biologics</strong></summary>
            <div>
                <ul><li>- <b>Eosinophil-Depleting Agents</b> (Benralizumab, Lirentelimab): ACG notes these achieve high rates of histologic response but often without significant symptom improvement.</li><li>- <b>Anti-IL-13</b> (Cendakimab): Showed promise in Phase 2 trials (ACG).</li><li>- <b>BSG</b>: Notes that novel biologics show promise but cannot yet be recommended outside of specific circumstances (e.g., co-existing allergic disease).</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Esophageal Dilation</strong></summary>
            <div>
                <ul><li>- <b>Consensus</b>: An effective and safe adjunctive therapy for treating fibrostenotic disease (strictures, narrowing) causing dysphagia.</li></ul>
                
        <details>
            <summary><strong>Indications & Approach</strong></summary>
            <div>
                <ul><li>- Used for patients with dysphagia from strictures.</li><li>- <b>Consensus</b>: Dilation should be combined with effective anti-inflammatory therapy, as it does not treat the underlying inflammation.</li><li>- <b>ACG</b>: Recommends a 'start low and go slow' approach, with a goal diameter of <q>≥16 mm</q> in adults.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Safety</strong></summary>
            <div>
                <ul><li>- <b>Consensus</b>: The procedure is safe.</li><li>- <b>ACG</b>: Cites a perforation risk of <q><b><0.5%</b></q>.</li><li>- <b>BSG</b>: Cites a perforation risk of <q><b>0.38%</b></q> in a meta-analysis, noting the risk is no higher than for other benign conditions.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Maintenance & Monitoring</strong></summary>
            <div>
                <ul><li>- EoE is a chronic disease that requires long-term management and monitoring.</li></ul>
                
        <details>
            <summary><strong>Maintenance Therapy (Consensus)</strong></summary>
            <div>
                <ul><li>- <b>Strong Recommendation</b>: Effective therapy (dietary or pharmacologic) should be continued long-term.</li><li>- Disease activity almost universally recurs when treatment is stopped.</li><li>- Long-term treatment may prevent or slow fibrostenotic progression.</li></ul>
                
        <details>
            <summary><strong>Dose Reduction</strong></summary>
            <div>
                <ul><li>- <b>ACG</b>: For pharmacologic treatments, consider identifying the lowest effective dose for long-term use, confirmed by endoscopy.</li><li>- <b>BSG</b>: Notes high relapse rates after STC withdrawal and recommends maintenance therapy.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Monitoring Response (Consensus)</strong></summary>
            <div>
                <ul><li>- <b>Strong Recommendation</b>: Evaluate response using a combination of <b>symptoms</b>, <b>endoscopy</b>, and <b>histology</b>.</li><li>- Monitoring symptoms alone is <u>insufficient</u> due to poor correlation with underlying inflammation.</li></ul>
                
        <details>
            <summary><strong>Timing of Follow-up Endoscopy</strong></summary>
            <div>
                <ul><li>- <b>ACG</b>: Generally <q>8-12 weeks</q> after starting a new therapy (PPI, STC, diet). May be <q>12-24 weeks</q> for dupilumab.</li><li>- <b>BSG</b>: Recommends endoscopy with biopsy <q>8-12 weeks</q> after initiating therapy.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Non-Invasive Monitoring (Future Direction)</strong></summary>
            <div>
                <ul><li>- Both guidelines acknowledge the need for less invasive monitoring.</li><li>- <b>ACG</b>: Mentions promising techniques like unsedated transnasal endoscopy, Cytosponge, and the Esophageal String Test.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Pediatric-Specific Considerations</strong></summary>
            <div>
                <ul><li>- Management in children has unique goals and challenges.</li></ul>
                
        <details>
            <summary><strong>Treatment Goals (Consensus)</strong></summary>
            <div>
                <ul><li>- In addition to symptom/histologic control, key goals are ensuring normal <b>growth</b>, <b>development</b> (including eating skills), and <b>nutrition</b>.</li><li>- <b>ACG</b>: Suggests evaluation by a feeding therapist and/or dietitian for children with feeding dysfunction.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Diagnostic Approach (BSG)</strong></summary>
            <div>
                <ul><li>- <b>Strong Recommendation (BSG)</b>: All children undergoing endoscopy for <u>any</u> upper GI symptoms should have esophageal biopsies taken to screen for EoE.</li><li>- This is due to the non-specific nature of symptoms in this population.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Evaluating Fibrostenosis</strong></summary>
            <div>
                <ul><li>- <b>ACG (Conditional Recommendation)</b>: Suggests an esophagram for children with dysphagia to evaluate for fibrostenotic disease, which can be missed on endoscopy.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Transition of Care (BSG)</strong></summary>
            <div>
                <ul><li>- BSG highlights the importance of a formal transition of care from pediatric to adult services.</li><li>- A structured transition may improve symptom control, adherence to therapy, and reduce emergency presentations.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Complications</strong></summary>
            <div>
                <ul><li>- Untreated or undertreated EoE can lead to significant complications.</li></ul>
                
        <details>
            <summary><strong>Fibrostenotic Disease (Strictures)</strong></summary>
            <div>
                <ul><li>- <b>Consensus</b>: A major complication of untreated, chronic inflammation.</li><li>- <b>BSG</b>: A delay in diagnosis is associated with a higher risk of stricture formation. A delay of <q>>20 years</q> had a stricture rate of <q>71%</q> vs. <q>17%</q> for a delay of <q><2 years</q>.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Food Bolus Obstruction (FBO)</strong></summary>
            <div>
                <ul><li>- <b>Consensus</b>: EoE is a leading cause of FBO in adults.</li><li>- <b>BSG</b>: Recommends maintenance therapy with topical steroids to reduce the risk of recurrent FBO.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Spontaneous Perforation</strong></summary>
            <div>
                <ul><li>- <b>BSG</b>: EoE is the most common cause of spontaneous esophageal perforation.</li><li>- It typically involves small tears with limited extravasation, unlike a Boerhaave's perforation.</li><li>- Management is often conservative with multidisciplinary input.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Psychological Impact (BSG)</strong></summary>
            <div>
                <ul><li>- BSG highlights the significant psychological impact of EoE, particularly from dietary therapy.</li><li>- Anxiety, depression, and social restrictions are common and can be alleviated by effective therapy.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
    </div>
    
</div>

<br>
<br>
<br>
<br>
<br>


<script>
// --- State Management for Expansion Level ---
let currentLevel = 1; 
const maxLevel = 10;
const minLevel = 1;

// --- Core Function to Set Mindmap Expansion ---
function setMindmapLevel(level) {
    const allDetails = document.querySelectorAll('.mindmap details');
    allDetails.forEach(detail => detail.removeAttribute('open'));
    allDetails.forEach(detail => {
        let depth = 0;
        let parent = detail.parentElement;
        while (parent && parent.tagName !== 'BODY') {
            if (parent.tagName === 'DETAILS') {
                depth++;
            }
            parent = parent.parentElement;
        }
        if (depth < level) {
            detail.setAttribute('open', '');
        }
    });
}

// --- Control Functions ---
function zoomIn() {
    if (currentLevel < maxLevel) {
        currentLevel++;
        setMindmapLevel(currentLevel);
    }
}

function zoomOut() {
    if (currentLevel > minLevel) {
        currentLevel--;
        setMindmapLevel(currentLevel);
    }
}

function resetView() {
    currentLevel = minLevel;
    setMindmapLevel(currentLevel);
}


// --- NEW: Function to Toggle Read/Quiz Mode ---
function toggleReadMode() {
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.classList.toggle('read-mode');
    }
}

// --- Draggable Controls ---
function dragElement(elmnt) {
    let pos1 = 0, pos2 = 0, pos3 = 0, pos4 = 0;
    const onMouseDown = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos3 = e.clientX;
        pos4 = e.clientY;
        document.onmouseup = closeDragElement;
        document.onmousemove = elementDrag;
    };
    const elementDrag = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos1 = pos3 - e.clientX;
        pos2 = pos4 - e.clientY;
        pos3 = e.clientX;
        pos4 = e.clientY;
        elmnt.style.top = (elmnt.offsetTop - pos2) + "px";
        elmnt.style.left = (elmnt.offsetLeft - pos1) + "px";
        elmnt.style.transform = "none";
        elmnt.style.bottom = "auto";
    };
    const closeDragElement = () => {
        document.onmouseup = null;
        document.onmousemove = null;
    };
    if (document.getElementById(elmnt.id)) {
        document.getElementById(elmnt.id).onmousedown = onMouseDown;
    } else {
        elmnt.onmousedown = onMouseDown;
    }
}




// --- Initial Setup ---
window.addEventListener('DOMContentLoaded', () => {
    // Set the initial mindmap view
    setMindmapLevel(currentLevel);

    // Get the draggable controls element
    const controls = document.getElementById('level-controls');
    if (controls) {
        dragElement(controls);
    }

    // --- CORRECTED & IMPROVED: Setup for Click-to-Reveal ---
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.addEventListener('click', function(event) {
            // Use .closest() to find the nearest parent <q> tag.
            // This is more robust than checking event.target.tagName.
            const quoteElement = event.target.closest('q');
            
            if (quoteElement) {
                // Add the 'is-revealed' class to show the text
                quoteElement.classList.add('is-revealed');
            }
        });
    }
});
</script>

</body>
</html>
